Trial Profile
Retrospective Observational Study of Nab-paclitaxel (Abraxane) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms AMBER
- Sponsors Celgene Corporation
- 28 Oct 2016 Status changed from not yet recruiting to discontinued.
- 29 Jan 2016 New trial record